Cullinan Oncology, Inc. (CGEM)
NASDAQ: CGEM · IEX Real-Time Price · USD
15.66
-2.40 (-13.29%)
At close: Apr 19, 2024, 4:00 PM
15.80
+0.14 (0.89%)
After-hours: Apr 19, 2024, 6:57 PM EDT
Cullinan Oncology Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Cullinan Oncology stock have an average target of 28.75, with a low estimate of 26 and a high estimate of 30. The average target predicts an increase of 83.59% from the current stock price of 15.66.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CGEM stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 2 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 4 | 4 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JonesTrading | JonesTrading | Strong Buy Maintains $22 → $26 | Strong Buy | Maintains | $22 → $26 | +66.03% | Apr 17, 2024 |
| BTIG | BTIG | Strong Buy Maintains $20 → $30 | Strong Buy | Maintains | $20 → $30 | +91.57% | Apr 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $34 → $29 | Strong Buy | Maintains | $34 → $29 | +85.19% | Apr 16, 2024 |
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Apr 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $34 | Strong Buy | Reiterates | $34 | +117.11% | Mar 14, 2024 |
Financial Forecast
Revenue This Year
1.58M
Revenue Next Year
15.23M
from 1.58M
Increased by 864.72%
EPS This Year
-3.81
from -3.69
EPS Next Year
-3.41
from -3.81
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 11.4M | 50.1M | 64.5M | n/a | 15.8M |
| Avg | 1.6M | 15.2M | 34.6M | n/a | 15.3M |
| Low | n/a | n/a | n/a | n/a | 14.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 3,072.3% | 323.2% | - | - |
| Avg | - | 864.7% | 127.0% | - | - |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -3.37 | -2.85 | -2.53 |
| Avg | -3.81 | -3.41 | -3.34 |
| Low | -4.36 | -3.87 | -4.10 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.